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Vincristine is a vinca alkaloid, a commonly used chemotherapy drug for treating leukemia, lymphoma, 
multiple myeloma and some pediatric cancers. Its major dose-limiting side effect is peripheral 
neuropathy. The current dosing of “standard-dose-for-all” ignores the genetic and phenotypic variations 
among different patients, and causes severe neuropathy in some patients while ineffectively treats the 
others. In the present study, we aim to discover novel biomarkers involved in vincristine-induced 
neuropathy and identify patients with varied metabolic characteristics. Thus treatment can be tailored 
accordingly to improve outcomes of vincristine treatment. Pre-dose and post-dose serum samples were 
collected from two groups of patients (low and high toxicity groups) at the beginning of treatment and 
at the end of treatments. Liquid chromatography–mass spectrometry (LC-MS) was used to identify and 
quantify metabolites in the samples. Metabolomics data analysis tools were utilized to analyze the raw 
spectrum obtained from LC-MS. From statistical analysis and modeling, we identified 27 compounds 
that showed a difference in intensity between low toxicity and high toxicity patients at the beginning of 
the treatment. Further verification against database and validation are needed to confirm the 
biomarkers to be able to be useful in clinics. Successful validation of the biomarkers will enable the 
clinicians to treat the patients according to their characteristics which will ultimately improve the 
survival and quality-of-life of cancer patients. 
 
